Smith & Nephew 3Q Sales Falls to $952M FeaturedWritten by Jaimie Oh | November 02, 2012
Smith & Nephew has reported third-quarter sales of $952 million, down from the $1.03 billion reported last year, according to a Bloomberg Businessweek report.
The sales decline was attributed to revenue loss from its biologics and clinical therapies business line, which spun off and was branded Bioventus. Broken out by business line, sales from Smith & Nephew's knee products fell 1 percent, while its sports medicine products saw an 8 percent hike.
© Copyright ASC COMMUNICATIONS 2011. Interested in LINKING to or REPRINTING this content? View our policies here.